Company Profile
GENFIT Stock Price, News & Catalysts
- Ticker:
- GNFT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France and listed in the U
Why the stock is moving
Current closing-price context is not available for GNFT.
Company overview
Liver-Disease Therapeutics and Diagnostics
GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure.
Iqirvo Economics
GENFIT receives milestones and royalties from Ipsen’s commercialization of Iqirvo in primary biliary cholangitis. Ipsen is also leading a Phase 3 study in primary sclerosing cholangitis, extending the molecule into another cholestatic liver disease.
MASH Diagnostics
The company has developed non-invasive diagnostic technology for metabolic dysfunction-associated steatohepatitis. It is commercializing a laboratory-developed test and preparing in vitro diagnostic development to support patient identification as the treatment market expands.
GNS561 in Cholangiocarcinoma
GNS561 is being evaluated in combination therapy for cholangiocarcinoma. Additional Phase 1b results are intended to inform a planned Phase 2 study.
NTZ in ACLF
NTZ is the lead internal program for acute-on-chronic liver failure. GENFIT plans to move the asset into Phase 2 proof-of-concept development in a condition with high short-term mortality and limited treatment options.
Future catalysts
- Additional Phase 1b GNS561 combination data in cholangiocarcinoma expected in mid-2026.
- Initiation of Phase 2 development for GNS561 targeted in the second half of 2026.
- Initiation of a Phase 2 NTZ trial in ACLF expected in the second half of 2026, with data in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does GENFIT do?
Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s commercialization of...
On which exchange is GNFT stock listed?
GENFIT (GNFT) is associated with NASDAQ, France and listed in the U, Biopharma.
What is proof-of-concept?
GENFIT plans to move the asset into Phase 2 proof-of-concept development in a condition with high short-term mortality and limited treatment options.
Which conditions is GENFIT targeting with proof-of-concept?
GENFIT is associated with metabolic disease based on its company overview and current catalyst commentary.
How does GENFIT describe recent progress with proof-of-concept?
Additional Phase 1b GNS561 combination data in cholangiocarcinoma expected in mid-2026. Initiation of Phase 2 development for GNS561 targeted in the second half of 2026. Initiation of a Phase 2 NTZ trial in ACLF expected in the second half of 2026, with data in 2027.
What is Liver-Disease?
Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases.
What should investors watch for with Liver-Disease?
Additional Phase 1b GNS561 combination data in cholangiocarcinoma expected in mid-2026. Initiation of Phase 2 development for GNS561 targeted in the second half of 2026. Initiation of a Phase 2 NTZ trial in ACLF expected in the second half of 2026, with data in 2027.
What is Therapeutics?
Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases.